Morningstar

Repligen Corporation to Present at Jefferies Global Healthcare Conference

Provided by GlobeNewswire

WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion on November 18th at 2:00 p.m. GMT.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions that support critical steps in the manufacturing and delivery of biologic drugs that improve human health worldwide. As a trusted partner to biopharmaceutical developers and manufacturers and CDMOs worldwide, we help improve productivity, simplify complex workflows, and advance the next generation of biologic therapies. Repligen technologies support the production of a broad range of biologic modalities, helping customers navigate evolving manufacturing challenges from process development through commercial production. Our global team combines deep scientific expertise, innovation, and a customer-focused mindset “inspiring advances in bioprocessing” to help solve complex challenges across biologics manufacturing. For more information, please visit our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com


The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

4 Growth Stocks to Buy While They’re Still Undervalued

Plus, the outlook for the AI trade after last week’s selloff.
David Sekera, CFA and Sarah Hansen

3 of the Best Core Stocks to Own

These core stocks with wide economic moats are good long-term investments if you can buy them at a discount.
Susan Dziubinski

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.
Tori Brovet

Your Year-End Financial Checklist: 5 Things to Tackle Before 2027

Christine Benz explains how to approach portfolio rebalancing, charitable giving, and retirement contributions.
Christine Benz and Valentina Djeljosevic

Why Morningstar Thinks Anthropic Is Worth $1.7 Trillion

A look at how we arrive at our base-case valuation for the AI lab, along with bull and bear scenarios.
Malik Ahmed Khan, CFA

Sponsor Center

Site Index
United States Flag United States

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.